Coherus Oncology (CHRS) Other Working Capital Changes (2013 - 2026)
Coherus Oncology (CHRS) posted Other Working Capital Changes of $468000.0 for Q1 2026, down 79.77% sequentially from $2.3 million in Q4 2025, and down 45.45% YoY from $858000.0 in Q1 2025.
Coherus Oncology (CHRS) Other Working Capital Changes (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Other Working Capital Changes for 11 years, with the latest figure at $468000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 45.45% year-over-year to $468000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.7 million (down 2114.46% YoY) and the FY2025 annual result came in at -$10.3 million, down 12695.12% from the prior year.
- Other Working Capital Changes eased to $468000.0 in Q1 2026 per CHRS's latest filing, from $2.3 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $7.6 million in Q1 2022 and troughed at -$5.9 million in Q3 2023.
- A 5-year average of -$211411.8 and a median of -$1.4 million in 2022 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes soared 1203.88% in 2024, then tumbled 3352.17% in 2025.
- Over 4 years, Other Working Capital Changes stood at -$5.0 million in 2023, then surged by 124.25% to $1.2 million in 2024, then jumped by 90.84% to $2.3 million in 2025, then tumbled by 79.77% to $468000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $468000.0, $2.3 million, and -$23.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Coherus Oncology | 214.42 Mn | 109.12 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.64 Mn |
| Jun 30, 2026 | -7.64 Mn |
| Jun 30, 2026 | -7.64 Mn |
| Mar 31, 2026 | 3.07 Mn |
| Mar 31, 2026 | 3.07 Mn |
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -4.47 Mn |
| Jun 30, 2025 | -4.47 Mn |
| Jun 30, 2025 | -4.47 Mn |
| Mar 31, 2025 | 5.33 Mn |
| Mar 31, 2025 | 5.33 Mn |
| Mar 31, 2025 | 5.33 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Dec 31, 2024 | -3.47 Mn |